Key Highlights:
- Shares eased around 3.8%, trading close to 28p and valuing the company at roughly £190m.
- First-half Revenue fell to £16.3m from £24.2m, with adjusted EBITDA turning negative against a positive £3.0m.
- The order book more than doubled to around £65m from £30m at the start of the year.
- Proposal volumes rose roughly 45% year on year, with guidance to high single-digit full-year revenue growth.
- Cash stood at around £13m at 30 June 2026, down modestly from £14.3m at the end of 2025.
After a bruising 2025 that stripped hVIVO of its record margins, the market wants proof that the recovery is real. A first-half update showing lower revenue but a doubled order book has left investors torn between a promising 2026-2028 pipeline and the near-term reality of a loss-making six months.
What happened to the shares?
hVIVO (LSE:HVO), the AIM-quoted specialist in human challenge trials, drifted lower again in mid-August 2026, with the screener snapshot behind this article pointing to a roughly 3.8% one-day decline. That figure comes from a single day’s trading and should be read as a marker of direction rather than a precise, verified close-to-close move. Around the same period the stock was trading close to its recent 28p level, having ended a prior session at 27.95p, which values the company at roughly £190m.
The slide fits a broader pattern. hVIVO spent much of 2025 falling from the highs it reached when it was posting record revenue and double-digit margins. The shares have since been rebuilding from a much lower base, and the recent softness looks like the market pausing to reassess after a busy run of contract announcements and a first-half trading update that laid bare just how second-half-weighted this year has become. For a stock this size, a move of a few percent on modest Volume is unremarkable in isolation; the more interesting question is what it says about sentiment heading into the important second half.
What is driving the story?
No single confirmed company-specific catalyst for the latest share-price movement was identified from the available public information. hVIVO’s most recent regulatory announcement of substance was its H1 2026 trading update on 23 July, and there is no fresh results release, contract award or guidance change dated on or immediately around the mid-August snapshot that would obviously explain a one-day fall of this magnitude.
That absence matters. When a small-cap moves without news, the likeliest explanations are technical or sentiment-driven: thin summer liquidity, profit-taking after earlier gains, sector read-across from other clinical-trial services and biotech names, or investors simply re-weighting the risk that this year’s promised second-half recovery does not fully materialise. The July update told a two-sided story — a weaker first half offset by a much larger order book — and in that kind of situation, shares can wobble as the bulls and bears argue over which half of the message deserves more weight. What can be said with confidence is that the setup is back-end loaded, and markets tend to discount execution risk before it is resolved.
Latest company developments
hVIVO has been unusually active in 2026, and the newsflow has been mostly constructive. In April the company published its 2025 final results and, separately, launched a unified Brand identity designed to present its consulting, clinical trials, human challenge trials and laboratory operations as one integrated services group. Commercial momentum followed quickly: a human challenge trial contract with ILiAD Biotechnologies for a whooping-cough programme on 22 April, a £6m influenza human challenge trial contract on 7 May, and a consultancy agreement with Decoy Therapeutics on 1 June.
The company also hosted a Capital Markets Day on 20 May, using the event to set out its strategy for cross-selling across its four service lines and for extracting value from the CRS and Cryostore businesses it acquired. On the housekeeping side, hVIVO announced a change of auditor on 13 July, a routine but noteworthy governance step.
The centrepiece was the 23 July H1 2026 trading update. First-half revenue came in at £16.3m, down sharply from £24.2m in the same period of 2025, and adjusted EBITDA turned negative in the mid-single-digit millions against a positive £3.0m a year earlier. Crucially, management framed 2026 as heavily second-half weighted, guiding to high single-digit full-year revenue growth and a return to positive adjusted EBITDA in the second half. The most eye-catching number was the order book, which management said had more than doubled to around £65m from £30m at the start of the year, with proposal volumes up roughly 45% year on year.
Financial position
The 2025 results underline why the recovery narrative carries weight. Full-year 2025 revenue fell to £46.8m from £62.7m in 2024, adjusted EBITDA collapsed to £1.4m from £16.4m, and the group swung to an operating loss of about £4.6m and a net loss of roughly £6.0m. No Dividend was declared. That was the hangover from a Demand air-pocket that hit the human challenge trial Business after its record year.
The balance sheet, however, remains a genuine cushion. hVIVO ended 2025 with £14.3m of cash and reported around £13m at 30 June 2026, a modest drawdown that management attributed to working-capital inflows from recent contract wins partly offsetting the loss-making first half. With no material Debt burden flagged and a cash pile close to a tenth of the market capitalisation, the company is not under financing pressure — an important point for a business whose Earnings can swing dramatically between years as large challenge-trial contracts are booked and delivered.
The bull case
The bull case rests on visibility. An order book that has more than doubled to £65m gives the clearest line of sight in years across 2026, 2027 and 2028, and a 45% jump in proposal volumes suggests the top of the funnel is refilling. If those contracts convert on schedule, the second half should deliver the revenue acceleration and return to positive adjusted EBITDA that management has guided towards, validating the recovery thesis. The recent run of wins — influenza, whooping cough and a growing consultancy stream — shows demand spread across pathogens and service types rather than concentrated in one programme. Layer in the CRS and Cryostore acquisitions, which management expects to become earnings accretive and cash generative during 2026, plus a debt-light balance sheet, and there is a credible path back towards the margins hVIVO commanded in its record year.
The bear case
The bear case is equally clear. A first half with falling revenue and negative adjusted EBITDA is a real result, not a forecast, and everything reassuring about 2026 is a promise about the six months still to come. Order books are contracted intentions, not delivered cash, and human challenge trials are complex, regulated and prone to timing slippage — any delay pushes revenue across period boundaries and can turn a guided recovery into another disappointment. The 2025 downgrade is fresh in investors’ memories, so patience for further second-half misses is thin. High single-digit full-year growth, even if achieved, still leaves revenue well below the 2024 peak, and margins have a long way to travel before the group looks like the cash machine it once was.
What could move the shares next?
The most obvious catalyst is the interim results and any accompanying commentary confirming that second-half contracts are converting on schedule — evidence of the promised EBITDA turn would matter more than the headline revenue line. Further contract awards, particularly large multi-year challenge-trial deals, would reinforce the order-book story, while any hint of slippage would do the opposite. Progress updates on integrating and monetising CRS and Cryostore, the cash trajectory into year-end, and broader sentiment towards biotech funding — which underpins client demand — are all worth watching. Given the stock’s sensitivity, even routine newsflow could move it sharply in the current thin-liquidity environment.
Investor takeaway
hVIVO (LSE:HVO) is a business mid-recovery, and the recent share-price softness reflects that unresolved tension rather than any confirmed bad news. The first half was weak, but the order book, proposal pipeline and balance-sheet strength give the second-half recovery story genuine substance. The open question is execution: whether contracted work converts into delivered revenue and a return to positive adjusted EBITDA on the timeline management has set out. Investors weighing the stock will want to balance the improved visibility against the reality that the payoff is still ahead and depends on a back-end-loaded year going to plan.






Please wait processing your request...